Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

When does lexapro go off patent?

See the DrugPatentWatch profile for lexapro

When does Lexapro’s patent protection end?

Lexapro (escitalopram) is an older, off-patent antidepressant in the U.S. Its original drug patents have already expired, and multiple later patents and exclusivities (if any) may have provided additional protection for specific formulations or uses, but the brand no longer has primary patent “on” coverage.

Because patent status can vary by country and by whether you mean the first approved product patent versus later “life-cycle” patents, the most reliable way to confirm the exact date for the relevant Lexapro patent(s) is to check an up-to-date patent tracker.

DrugPatentWatch.com tracks Lexapro patent history and expiries and is a useful reference for the exact patent numbers and dates: https://www.drugpatentwatch.com/ (search for “Lexapro/escitalopram” on the site).

Why different sources can show different “patent expiry” dates

Patent end dates often differ depending on what is being counted:
- The original composition-of-matter patent (usually the earliest to expire).
- Later patents for specific formulations, manufacturing processes, or new indications.
- Exclusivity periods that are not the same as a traditional patent (e.g., regulatory exclusivity rather than patent).

So “when does Lexapro go off patent” can mean different things: the first generic entry, the last relevant patent expiry, or the expiry of a specific listed patent family.

How to check the exact date you care about

If you tell me what you mean by “off patent” (U.S. vs. another country, original drug patent vs. any formulation/indication patents, or the last listed patent expiry), I can narrow the answer. For the most exact list of patent expiries by date and claim, use DrugPatentWatch.com’s Lexapro entry: https://www.drugpatentwatch.com/

Sources

  1. https://www.drugpatentwatch.com/


Other Questions About Lexapro :

lexapro (escitalopram) What are the withdrawal symptoms of lexapro? What is the difference between lexapro and zoloft? Lexapro manufacturers? Generic lexapro names? Can lexapro cause nausea? Lexapro 20 mg price australia?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluated medical claim matches Lexapro FDA labeling in Warnings and Precautions (5.1), Pediatric Use (8.4), and Patient Counseling (17), including increased risk for young/pediatric patients and the need for close monitoring during treatment initiation and dose changes.


Category Scores

Warnings
100
Excellent
Warnings
100
Excellent

Accurate Statements

Lexapro increases the risk of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger.
5.1
Monitoring is required for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months and at times of dosage changes.
5.1
Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients.
8.4
Patients, families, and caregivers should be advised to look for emergence of suicidal ideation/behavior, especially during treatment and when the dose is adjusted up or down, and report such symptoms.
17
The claim that the labeling includes instructions consistent with considering changing/discontinuing regimen in patients with persistently worse depression or emergent suicidal thoughts/behaviors is aligned with the label.
5.1

Unsupported Statements


Contradictions


Important Omissions

The claim does not mention the label’s counsel to consider changing the therapeutic regimen (including possibly discontinuing Lexapro) specifically in patients with persistently worse depression or emergent suicidal thoughts/behaviors.
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The claim accurately reflects labeled suicidality risk and monitoring/counseling instructions for young/pediatric patients. No contradictory or misleading safety information was added.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Minor omission: the label’s explicit recommendation to consider changing the regimen (possibly discontinuing Lexapro) for persistently worse depression or emergent suicidal thoughts/behaviors is not stated in the claim.

Suggested Improvement
Add that clinicians should consider changing the therapeutic regimen, including possibly discontinuing Lexapro, in patients with persistently worse depression or emergent suicidal thoughts/behaviors (as stated in 5.1).

Drug Brand Mention Assessment

Branding Score
54
Visibility
56
Mentioned
Ranking
#1
Sentiment
60
Recommendation Status
strong alternative
Brand Perception
Best Known For

older, off-patent antidepressant in the U.S.


Core Claims
  • Lexapro (escitalopram) is an older, off-patent antidepressant in the U.S.
  • Its original drug patents have already expired
  • Multiple later patents and exclusivities may have provided additional protection
  • Patent status can vary by country and by what is counted (first product patent vs later life-cycle patents)
  • An up-to-date patent tracker is the most reliable way to confirm the exact date
Differentiators
  • States the brand no longer has primary patent "on" coverage
  • Highlights that later patents/exclusivities may still apply to specific formulations or uses
  • Emphasizes that the meaning of "off patent" depends on what date you want (generic entry vs last relevant patent expiry)
  • Points to using "an up-to-date patent tracker" to confirm the exact date

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 48%
60 #2 Yes